Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cann Group ( (AU:CAN) ) has issued an announcement.
Cann Group Limited has announced an Extraordinary General Meeting (EGM) scheduled for May 30, 2025, to seek shareholder approval for several resolutions related to recent financing transactions. These include ratifications and approvals for the issuance of shares and options as part of private placements and convertible notes, aimed at securing funding to optimize production and support strategic growth. The board supports these resolutions, which are expected to provide the company with the flexibility to pursue future expansion and growth opportunities.
More about Cann Group
Cann Group Limited is an Australian company focused on enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The company operates world-class research, cultivation, and GMP manufacturing facilities in Melbourne and a large-scale facility near Mildura, Victoria. Cann Group offers a range of dried flower and oil products, active pharmaceutical ingredients, and extracts to customers both in Australia and internationally. It also owns Satipharm and its patent-protected capsule technology.
YTD Price Performance: 80.0%
Average Trading Volume: 300
Technical Sentiment Signal: Buy
Current Market Cap: $6.2M
See more data about CAN stock on TipRanks’ Stock Analysis page.